$5.95
7.40% yesterday
Nasdaq, Nov 15, 09:50 pm CET
ISIN
US23285D1090
Symbol
CTKB

Cytek BioSciences Inc Stock price

$5.95
+0.61 11.42% 1M
-0.15 2.46% 6M
-3.17 34.76% YTD
+0.24 4.20% 1Y
-17.21 74.31% 3Y
-12.81 68.28% 5Y
-12.81 68.28% 10Y
Nasdaq, Closing price Fri, Nov 15 2024
-0.47 7.32%
ISIN
US23285D1090
Symbol
CTKB
Sector

Key metrics

Market capitalization $826.97m
Enterprise Value $583.24m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 20.28
EV/Sales (TTM) EV/Sales 2.90
P/S ratio (TTM) P/S ratio 4.11
P/B ratio (TTM) P/B ratio 2.16
Revenue growth (TTM) Revenue growth 9.88%
Revenue (TTM) Revenue $201.21m
EBIT (operating result TTM) EBIT $-23.65m
Free Cash Flow (TTM) Free Cash Flow $28.76m
Cash position $277.81m
EPS (TTM) EPS $-0.08
P/E forward negative
P/S forward 4.04
EV/Sales forward 2.85
Short interest 4.20%
Show more

Is Cytek BioSciences Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Cytek BioSciences Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Cytek BioSciences Inc forecast:

4x Buy
67%
2x Hold
33%

Analyst Opinions

6 Analysts have issued a Cytek BioSciences Inc forecast:

Buy
67%
Hold
33%

Financial data from Cytek BioSciences Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
201 201
10% 10%
100%
- Direct Costs 91 91
18% 18%
45%
111 111
4% 4%
55%
- Selling and Administrative Expenses 83 83
2% 2%
41%
- Research and Development Expense 41 41
6% 6%
20%
-13 -13
27% 27%
-7%
- Depreciation and Amortization 10 10
43% 43%
5%
EBIT (Operating Income) EBIT -24 -24
7% 7%
-12%
Net Profit -10 -10
28% 28%
-5%

In millions USD.

Don't miss a Thing! We will send you all news about Cytek BioSciences Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Cytek BioSciences Inc Stock News

Neutral
GlobeNewsWire
8 days ago
FREMONT, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB) has introduced an Enhanced Small Particle (ESP™) Detection Option for its Cytek Aurora™ CS system.
Neutral
Seeking Alpha
10 days ago
Cytek Biosciences, Inc. (NASDAQ:CTKB ) Q3 2024 Earnings Conference Call November 5, 2024 4:30 PM ET Company Participants Paul Goodson - Investor Relations Wenbin Jiang - Chief Executive Officer William McCombe - Chief Financial Officer Conference Call Participants Tejas Savant - Morgan Stanley Brendan Smith - TD Cowen Mason Carrico - Stephens John Barnidge - Piper Sandler Andrew Cooper - Raymon...
Neutral
GlobeNewsWire
about 2 months ago
FREMONT, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB) is set to elevate its presence at this year's premier clinical industry events across the globe.
More Cytek BioSciences Inc News

Company Profile

Cytek Biosciences, Inc. is a life sciences technology company engages in the provision of cell analysis tools by leveraging novel technical approaches. Its products include Cytek Aurora CS, Cytek Aurora, Cytek Northern Lights, and Cytek NL-CLC. The company was founded by Wenbin Jiang and Ming Yan in December 2014 and is headquartered in Fremont, CA.

Head office United States
CEO Wen Jiang
Employees 676
Founded 1992
Website cytekbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today